Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001;271:171–82.

Article  CAS  PubMed  Google Scholar 

Zhuang L, Falquet L, Trueb B. Genome-wide comparison of FGFRL1 with structurally related surface receptors. Exp Ther Med. 2010;1:161–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149:121–30.

Article  CAS  PubMed  Google Scholar 

Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.

Article  CAS  PubMed  Google Scholar 

Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264–79.

Article  CAS  PubMed  Google Scholar 

Markham A, Erdafitinib. First Global approval. Drugs. 2019;79:1017–21.

Article  CAS  PubMed  Google Scholar 

Syed YY. Futibatinib: first approval. Drugs. 2022;82:1737–43.

Article  CAS  PubMed  Google Scholar 

Hoy SM, Pemigatinib. First Approval Drugs. 2020;80:923–9.

PubMed  Google Scholar 

Kang C. Infigratinib: first approval. Drugs. 2021;81:1355–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert Rev Anticancer Ther. 2023;23:351–9.

Article  CAS  PubMed  Google Scholar 

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al. Docetaxel plus Nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.

Article  CAS  PubMed  Google Scholar 

Zhang J, Li Y. Therapeutic uses of FGFs. Semin Cell Dev Biol. 2016;53:144–54.

Article  CAS  PubMed  Google Scholar 

Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernandes-Freitas I, Owen BM. Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol. 2015;25:30–5.

Article  CAS  PubMed  Google Scholar 

Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–87.

Article  CAS  PubMed  Google Scholar 

Jing Q, Wang Y, Liu H, Deng X, Jiang L, Liu R, Song H, Li J. FGFs: crucial factors that regulate tumour initiation and progression. Cell Prolif. 2016;49:438–47.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Wei Z, Li H, Dang Q, Zhang Z, Wang L, Gao W, Zhang P, Yang D, Liu J, et al. Clinicopathological significance of fibroblast growth factor 1 in non-small cell lung cancer. Hum Pathol. 2015;46:1821–8.

Article  CAS  PubMed  Google Scholar 

Liu P, Zhang R, Yu W, Ye Y, Cheng Y, Han L, Dong L, Chen Y, Wei X, Yu J. FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells. Biomaterials. 2017;149:63–76.

Article  CAS  PubMed  Google Scholar 

Li L, Zhang S, Wei L, Wang Z, Ma W, Liu F, Qian Y. FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer. Oncol Lett. 2018;16:2490–4.

PubMed  PubMed Central  Google Scholar 

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, et al. Fibroblast growth factor receptor 1 and related ligands in small-cell Lung Cancer. J Thorac Oncol. 2015;10:1083–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan H, Li ZM, Shao J, Ji WX, Xia W, Lu S. FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. J Exp Clin Cancer Res. 2017;36:72.

Article  PubMed  PubMed Central  Google Scholar 

Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W, Lu S. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018;37:5340–54.

Article  CAS  PubMed  Google Scholar 

Suzuki T, Yasuda H, Funaishi K, Arai D, Ishioka K, Ohgino K, Tani T, Hamamoto J, Ohashi A, Naoki K, et al. Multiple roles of extracellular fibroblast growth factors in lung cancer cells. Int J Oncol. 2015;46:423–9.

Article  CAS  PubMed  Google Scholar 

Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Embo j. 2006;25:3078–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tai AL, Sham JS, Xie D, Fang Y, Wu YL, Hu L, Deng W, Tsao GS, Qiao GB, Cheung AL, Guan XY. Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma. Cancer. 2006;106:146–55.

Article  CAS  PubMed  Google Scholar 

Liu D, Liu H, Gan J, Zeng S, Zhong F, Zhang B, Zhang Z, Zhang S, Jiang L, Wang G, et al. LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 amplification mediated Gefitinib Resistance in NSCLC. Front Pharmacol. 2022;13:918317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi L, Song W, Li L, Cao L, Yu Y, Song C, Wang Y, Zhang F, Li Y, Zhang B, Cao W. FGF4 induces epithelial-mesenchymal transition by inducing store-operated calcium entry in lung adenocarcinoma. Oncotarget. 2016;7:74015–30.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Wu T, Li F, Cheng Y, Han Q, Lu X, Lu S, Xia W. FGF19 is Coamplified with CCND1 to promote proliferation in lung squamous cell carcinoma and their combined inhibition shows improved efficacy. Front Oncol. 2022;12:846744.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Wu T, Wang Y, Chen Z, Chen J, Lu S, Xia W. Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis. Cell Oncol (Dordr). 2023;46:437–50.

Article  CAS  PubMed  Google Scholar 

Kim HR, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, et al. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017;28:1250–9.

Article  CAS